Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of down syndrome-related developmental cognitive deficits

Human Molecular Genetics

Volumn 23, Issue 3, 2014, Pages 578-589

  Zhang, Li ^a,b   Meng, Kai ^b   Jiang, Xiaoling ^b   Liu, Chunhong ^b   Pao, Annie ^b   Belichenko, Pavel V ^d   Kleschevnikov, Alexander M ^d   Josselyn, Sheena ^e   Liang, Ping ^f   Ye, Ping ^g   Mobley, William C ^d   Yu, Y Eugene ^b,c  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f BROCK UNIVERSITY   (Canada)

^g WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CBR1 GENE; CHROMOSOME 10; CHROMOSOME 16; CHROMOSOME 17; COGNITIVE DEFECT; CONTROLLED STUDY; DOWN SYNDROME; ELECTROPHYSIOLOGICAL PROCEDURES; EXCITATORY POSTSYNAPTIC POTENTIAL; FAM3B GENE; GENE; HIPPOCAMPUS; HSA21 GENE; HUMAN CHROMOSOME; IN VITRO STUDY; MORRIS WATER MAZE TEST; MOUSE; MOUSE MUTANT; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION;

ALCOHOL OXIDOREDUCTASES; ANIMALS; CHROMOSOMES, HUMAN, PAIR 21; COGNITION DISORDERS; CYTOKINES; DISEASE MODELS, ANIMAL; DOWN SYNDROME; HIPPOCAMPUS; HUMANS; LONG-TERM POTENTIATION; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, MUTANT STRAINS; NEOPLASM PROTEINS;

EID: 84892466245     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt446     Document Type: Article

References (43)

1. Pennington, B.F., Moon, J., Edgin, J., Stedron, J. and Nadel, L. (2003) The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev., 74, 75-93.
2. Pulsifer, M.B. (1996) The neuropsychology of mental retardation. J. Int. Neuropsychol. Soc., 2, 159-176.
3. Chapman, R.S. and Hesketh, L.J. (2000) Behavioral phenotype of individuals with Down syndrome. Ment. Retard. Dev. Disabil. Res. Rev., 6, 84-95.
4. Davisson, M.T., Schmidt, C. and Akeson, E.C. (1990) Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog. Clin. Biol. Res., 360, 263-280.
5. Reeves, R.H., Irving, N.G., Moran, T.H., Wohn, A., Kitt, C., Sisodia, S.S., Schmidt, C., Bronson, R.T. and Davisson, M.T. (1995) A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet., 11, 177-184.
6. Duchon, A., Raveau, M., Chevalier, C., Nalesso, V., Sharp, A.J. and Herault, Y. (2011) Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. Mamm. Genome, 22, 674-684.
7. Reinholdt, L.G., Ding, Y., Gilbert, G.J., Czechanski, A., Solzak, J.P., Roper, R.J., Johnson, M.T., Donahue, L.R., Lutz, C. and Davisson, M.T. (2011) Molecular characterization of the translocation breakpoints in the Down syndrome mouse model Ts65Dn. Mamm. Genome, 22, 685-691.
8. Kleschevnikov, A.M., Belichenko, P.V., Villar, A.J., Epstein, C.J., Malenka, R.C. and Mobley, W.C. (2004) Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci., 24, 8153-8160.
9. Siarey, R.J., Stoll, J., Rapoport, S.I. and Galdzicki, Z. (1997) Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down syndrome. Neuropharmacology, 36, 1549-1554.
10. Li, Z., Yu, T., Morishima, M., Pao, A., LaDuca, J., Conroy, J., Nowak, N., Matsui, S., Shiraishi, I. and Yu, Y. (2007) Duplication of the entire 22.9-Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities. Hum. Mol. Genet., 16, 1359-1366.
11. Yu, T., Liu, C., Belichenko, P., Clapcote, S.J., Li, S., Pao, A., Kleschevnikov, A., Bechard, A.R., Asrar, S., Chen, R. et al. (2010) Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. Brain Res., 1366, 162-171.
12. Yu, T., Li, Z., Jia, Z., Clapcote, S.J., Liu, C., Li, S., Asrar, S., Pao, A., Chen, R., Fan, N. et al. (2010) A mouse model of Down syndrome trisomic for all humanchromosome21 syntenic regions.Hum.Mol. Genet., 19, 2780-2791.
13. Korbel, J.O., Tirosh-Wagner, T., Urban, A.E., Chen, X.N., Kasowski, M., Dai, L., Grubert, F., Erdman, C., Gao, M.C., Lange, K. et al. (2009) The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis ofhumansegmental trisomies. Proc. Natl Acad. Sci. USA, 106, 12031-12036.
14. Korenberg, J.R., Chen, X.N., Schipper, R., Sun, Z., Gonsky, R., Gerwehr, S., Carpenter, N., Daumer, C., Dignan, P. and Disteche, C. (1994) Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc. Natl Acad. Sci. USA, 91, 4997-5001.
15. Lyle, R., Bena, F., Gagos, S., Gehrig, C., Lopez, G., Schinzel, A., Lespinasse, J., Bottani, A., Dahoun, S., Taine, L. et al. (2009) Genotype-phenotype correlations inDownsyndrome identified by arrayCGHin 30 cases of partial trisomy and partial monosomy chromosome 21. Eur. J. Hum. Genet., 17, 454-466.
16. Sinet, P.M., Theophile, D., Rahmani, Z., Chettouh, Z., Blouin, J.L., Prieur, M., Noel, B. and Delabar, J.M. (1994) Mapping of the Down syndrome phenotype on chromosome 21 at the molecular level. Biomed. Pharmacother., 48, 247-252.
17. Delabar, J.M., Theophile, D., Rahmani, Z., Chettouh, Z., Blouin, J.L., Prieur, M., Noel, B. and Sinet, P.M. (1993) Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur. J. Hum. Genet., 1, 114-124.
18. Korenberg, J.R., Kawashima, H., Pulst, S.M., Ikeuchi, T., Ogasawara, N., Yamamoto, K., Schonberg, S.A., West, R., Allen, L., Magenis, E. et al. (1990) Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. Am. J. Hum. Genet., 47, 236-246.
19. Olson, L.E., Richtsmeier, J.T., Leszl, J. and Reeves, R.H. (2004) A chromosome 21 critical region does not cause specific Down syndrome phenotypes. Science, 306, 687-690.
20. Olson, L.E., Roper, R.J., Sengstaken, C.L., Peterson, E.A., Aquino, V., Galdzicki, Z., Siarey, R., Pletnikov, M., Moran, T.H. and Reeves, R.H. (2007) Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Hum. Mol. Genet., 16, 774- 782.
21. Bliss, T.V. and Collingridge, G.L. (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 361, 31-39.
22. Malenka, R.C. and Nicoll, R.A. (1999) Long-term potentiation-a decade of progress?. Science, 285, 1870-1874.
23. Braudeau, J., Delatour, B., Duchon, A., Pereira, P.L., Dauphinot, L., de Chaumont, F., Olivo-Marin, J.C., Dodd, R.H., Herault, Y. and Potier, M.C. (2011) Specific targeting of the GABA-A receptor alpha5 subtype by a selective inverse agonist restores cognitive deficits in Downsyndrome mice. J. Psychopharmacol., 25, 1030-1042.
24. Contestabile, A., Greco, B., Ghezzi, D., Tucci, V., Benfenati, F. and Gasparini, L. (2013) Lithium rescues synaptic plasticity and memory in Down syndrome mice. J. Clin. Invest., 123, 348-361.
25. Fernandez, F., Morishita, W., Zuniga, E., Nguyen, J., Blank, M., Malenka, R.C. and Garner, C.C. (2007) Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci., 10, 411-413.
26. Gardiner, K.J. (2010) Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends Pharmacol. Sci., 31, 66-73.
27. Kleschevnikov, A.M., Belichenko, P.V., Faizi, M., Jacobs, L.F., Htun, K., Shamloo, M. and Mobley, W.C. (2012) Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J. Neurosci., 32, 9217-9227.
28. Martinez-Cue, C., Martinez, P., Rueda, N., Vidal, R., Garcia, S., Vidal, V., Corrales, A., Montero, J.A., Pazos, A., Florez, J. et al. (2013) Reducing GABAA alpha5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of Down syndrome. J. Neurosci., 33, 3953-3966.
29. Hanney, M., Prasher, V., Williams, N., Jones, E.L., Aarsland, D., Corbett, A., Lawrence, D., Yu, L.M., Tyrer, S., Francis, P.T. et al. (2012) Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet, 379, 528-536.
30. Belichenko, N.P., Belichenko, P.V., Kleschevnikov, A.M., Salehi, A., Reeves, R.H. and Mobley, W.C. (2009) The 'Down syndrome critical region' is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. J. Neurosci., 29, 5938-5948.
31. Pereira, P.L., Magnol, L., Sahun, I., Brault, V., Duchon, A., Prandini, P., Gruart, A., Bizot, J.C., Chadefaux-Vekemans, B., Deutsch, S. et al. (2009) A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code ofDownsyndrome.Hum.Mol. Genet., 18, 4756-4769.
32. Hammerle, B., Ulin, E., Guimera, J., Becker, W., Guillemot, F. and Tejedor, F.J. (2011) Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling. Development, 138, 2543-2554.
33. Fernandez-Martinez, J., Vela, E.M., Tora-Ponsioen, M., Ocana, O.H., Nieto, M.A. and Galceran, J. (2009) Attenuation of Notch signalling by the Down-syndrome-associated kinaseDYRK1A.J. Cell Sci., 122, 1574-1583.
34. Kelly, P.A. and Rahmani, Z. (2005) DYRK1A enhances the mitogen-activated protein kinase cascade in PC12 cells by forming a complex with Ras, B-Raf, and MEK1. Mol. Biol. Cell, 16, 3562-3573.
35. Gwack, Y., Sharma, S., Nardone, J., Tanasa, B., Iuga, A., Srikanth, S., Okamura, H., Bolton, D., Feske, S., Hogan, P.G. et al. (2006) A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature, 441, 646-650.
36. Mark, M.D. and Herlitze, S. (2000) G-protein mediated gating of inward-rectifier K+ channels. Eur. J. Biochem., 267, 5830-5836.
37. Yamada, M., Inanobe, A. and Kurachi, Y. (1998) G protein regulation of potassium ion channels. Pharmacol. Rev., 50, 723-760.
38. Harashima, C., Jacobowitz, D.M., Stoffel, M., Chakrabarti, L., Haydar, T.F., Siarey, R.J. and Galdzicki, Z. (2006) Elevated expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in cerebellar unipolar brush cells of aDownsyndrome mouse model. Cell. Mol. Neurobiol., 26, 719-734.
39. Cramer, N.P., Best, T.K., Stoffel, M., Siarey, R.J. and Galdzicki, Z. (2010) GABAB-GIRK2-mediated signaling in Down syndrome. Adv. Pharmacol., 58, 397-426.
40. Domek-Lopacinska, K. and Strosznajder, J.B. (2005) Cyclic GMP metabolism and its role in brain physiology. J. Physiol. Pharmacol., 56(Suppl. 2), 15-34.
41. Domek-Lopacinska, K.U. and Strosznajder, J.B. (2010) Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease. Mol. Neurobiol., 41, 129-137.
42. Reneerkens, O.A., Rutten, K., Steinbusch, H.W., Blokland, A. and Prickaerts, J. (2009) Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl.), 202, 419- 443.
43. Zhang, L., Meng, K., Li, Y.H. and Han, T.Z. (2009) NR2A-containing NMDA receptors are required for L-LTP induction and depotentiation in CA1 region of hippocampal slices. Eur. J. Neurosci., 29, 2137-2144.